Fig. 5.
Sleep-wake profiles of animals during sleep deprivation. A: average time (in minutes) spent awake and in non-REM sleep during 2-h sleep deprivation following SS-rBF administration of the A1R agonist, CGS21680, or vehicle. There were no significant between-group differences (time awake, t = 0.78, NS; time in non-REM sleep t = −0.72 NS). REM sleep was completely suppressed in all rats during sleep deprivation. B: average time spent awake and in non-REM sleep during 3 h of sleep deprivation in groups of rats that received intracerebroventricular infusion of vehicle or A2AR antagonist, ZM241385 (5 or 25 nmol) or vehicle during the final 2 h of the sleep deprivation period. Although there was a significant overall effect of drug and vehicle treatment on time spent in non-REM sleep during sleep deprivation (F2,15 = 4.73; P < 0.01), the maximum difference in mean time spent asleep across groups of 4.0 min would not be expected to have a significant functional impact on subsequent recovery sleep.